Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma

Next Previous
Trial Profile

A 26-Week Open-Label Study to Assess the Long-Term Safety of Fluticasone Propionate Multidose Dry Powder Inhaler and Fluticasone Propionate/Salmeterol Multidose Dry Powder Inhaler in Patients 12 Years of Age and Older With Persistent Asthma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Most Recent Events

  • 30 Jan 2017 According to a Teva Pharmaceuticals media release, the U.S. Food and Drug Administration (FDA) approved AirDuoTM RespiClick (fluticasone propionate and salmeterol inhalation powder) and ArmonAirTM RespiClick (fluticasone propionate inhalation powder) for adolescent and adult patients with asthma.
  • 07 Nov 2016 According to a Teva Pharmaceuticals media release, data from this trial will be presented at the 2016 American College of Allergy, Asthma & Immunology (ACAAI) Annual Scientific Meeting
  • 28 Jun 2016 According to Teva Pharmaceuticals media release, company announced the U.S. Food and Drug Administration (FDA) has accepted for review the company's new drug applications (NDAs) for two products for adolescent and adult patients with asthma with FDA Regulatory Action expected during the first quarter of 2017.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top